

Title (en)

TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID

Title (de)

BEHANDLUNG VON AUTISTISCHEN ERKRANKUNGEN MIT GLYCYL-L-2-METHYLPROLYL-L-GLUTAMINSÄURE

Title (fr)

TRAITEMENT DE TROUBLES DU SPECTRE AUTISTIQUE À L'AIDE DE L'ACIDE GLYCYL-L-2-MÉTHYLPROLYL-L-GLUTAMIQUE

Publication

EP 2928300 A4 20160713 (EN)

Application

EP 13858943 A 20131126

Priority

- US 201261730829 P 20121128
- US 2013072049 W 20131126

Abstract (en)

[origin: WO2014085480A1] This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyL-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.

IPC 8 full level

A01N 43/46 (2006.01); **A61K 31/41** (2006.01); **A61P 25/28** (2006.01); **C07D 207/00** (2006.01)

CPC (source: EP)

A61K 31/40 (2013.01); **A61K 38/06** (2013.01); **A61P 25/00** (2017.12); **A61P 25/18** (2017.12); **A61P 25/28** (2017.12); **A61P 43/00** (2017.12); **C07D 207/16** (2013.01); **C07K 5/0806** (2013.01)

Citation (search report)

- [Y] WO 2011146109 A2 20111124 - SINAI SCHOOL MEDICINE [US], et al
- [Y] WO 02094856 A2 20021128 - NEURONZ LTD [NZ], et al
- [Y] US 2011112033 A1 20110512 - GLUCKMAN PETER DAVID [NZ], et al
- [Y] WENLIN LIAO ET AL: "MeCP2+/ mouse model of RTT reproduces auditory phenotypes associated with Rett syndrome and replicate select EEG endophenotypes of autism spectrum disorder", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 46, no. 1, 31 December 2011 (2011-12-31), pages 88 - 92, XP028467473, ISSN: 0969-9961, [retrieved on 20120109], DOI: 10.1016/J.NBD.2011.12.048
- [Y] ADRIAN BIRD: "The methyl-CpG-binding protein MeCP2 and neurological disease", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 36, no. 4, 1 August 2008 (2008-08-01), GB, pages 575 - 583, XP055276490, ISSN: 0300-5127, DOI: 10.1042/BST0360575
- See references of WO 2014085480A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2014085480 A1 20140605; AU 2013352294 A1 20150709; BR 112015012506 A2 20170711; CA 2929286 A1 20140605; EP 2928300 A1 20151014; EP 2928300 A4 20160713; JP 2016506380 A 20160303

DOCDB simple family (application)

US 2013072049 W 20131126; AU 2013352294 A 20131126; BR 112015012506 A 20131126; CA 2929286 A 20131126; EP 13858943 A 20131126; JP 2015545191 A 20131126